Back

Short- and long-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure

30 August 2025 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Heart failure therapy across the spectrum Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Venera Bytyqi

University Hospital Erlangen, Erlangen (Germany)

5 More presentations in this session

Presentation thumbnail
Empagliflozin versus dapagliflozin in heart failure
Mr K. Bonnesen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Early diagnosis of Wild-type Transthyretin Amyloidosis Cardiomyopathy by optimized screening of patients undergoing Carpal Tunnel Syndrome Surgery (CACTuS II)
Mrs S. Fensman (Aarhus N, DK)
Abstract Slides Video
Presentation thumbnail
Home-based rehabilitation in patients with chronic heart failure after acute decompensation: primary results of the PILOT-CRHF trial
Doctor A. Reuser (Leipzig, DE)
Abstract Slides Video
Presentation thumbnail
Efficacy of early angiotensin receptor/neprilysin inhibition in post-myocardial infarction patients: a meta-analysis of randomized controlled trials
Associate Professor C. Hsu (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Remote rapid titration of heart failure therapies
Doctor A. Abdel-Gadir (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure therapy across the spectrum

The Event

Event poster

ESC Congress 2025

30 August 2025 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Empagliflozin reduces extracellular volume and myocardial sodium content in patients with heart failure and preserved ejection fraction and correlates with reverse cardiac remodeling (EMPAG CMR-HF)
thumbnail
Congress Presentation
Acute diuretic effect of empagliflozin in de novo heart failure: a secondary analysis of the EMPAG-HF trial
thumbnail
Congress Presentation
Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources